An Apology to Subscribers, and Five Random ID/HIV Questions to Ponder

May 6th, 2015

An Apology to Subscribers, and Five Random ID/HIV Questions to Ponder

Some of you have been kind enough to enter your email address in the little box on the right side of this page, which gives you a “subscription” to this site. It looks like this:

We thank you for signing up! Delivery is usually prompt and reliable (even during this past winter’s historic snowstorms), and the price can’t be beat (free).

But this week, due to a fascinating technical glitch — text copied from the FDA web site included a prohibited character, a little empty box — no e-mail notification was sent out with the latest post. Our apologies! For the record, the post included various thoughts on the nettlesome problem of fat accumulation syndromes in HIV, and a terrific video from that famous ID specialist John Stewart.

In exchange for this inconvenience, we’re offering a full refund — plus a bonus Five Random ID/HIV Questions to Ponder

Could this investigational zoster vaccine really be 97% effective? Total game-changer for shingles prevention if it turns out to be this effective and safe.
Are we going to call the newest azole antifungal “isavuconazole,” or by it’s weird real name, “isavuconazonium?” Strongly hoping the former.
What percentage of ID doctors know exactly what “MALDI-TOF” stands for? My guess: 54%.
Has anyone prescribed elvitegravir or cobicistat as individual agents? Probably — it’s a big country. But why did they do this?
Why did several people in Colorado catch plague from a sick dog? Yikes, a few chewed shoes you expect. But plague?

Speaking of plague …

HIV and ID Observations

An ongoing dialogue on HIV/AIDS, infectious diseases,
all matters medical, and some not so medical.

May 6th, 2015